This presentation will introduce GARDskin Dose-Response assay, a novel approach for the assessment of relative skin sensitizing potency on a continuous scale.
Results demonstrate that induction of toxicity pathways in GARDskin Dose-Response appears to be highly dose-dependent, and the lowest concentration required to induce a positive classification in the assay correlates strongly and significantly with both LLNA EC3 and human NOEL values.
A case study will be used to illustrate how the experimentally derived values from the GARDskin Dose-response assay can be used for CLP potency assessments, potency rankings of potential candidate molecules, or as a point of departure for quantitative risk assessment without having to revert to animal experimentation.
Featured Speakers
Andy Forreryd, PhD
Dr Andy Forreryd holds a Master of Science in molecular biotechnology from the Faculty of Engineering LTH at Lund University and a Doctor of philosophy in Immunotechnology from Lund University. He has many years of experience working with in vitro assay development, genomics, and machine learning. He is co-developer of the GARD® platform for the assessment of chemical sensitizers and inventor of two patents related to the technology.
